Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A

Amgen, J&J and Sanofi size up Horizon as Big Pharma renews interest in rare disease M&A

By Angus Liu

Rare disease drug maker Horizon Therapeutics said it has drawn buyout interest from pharma juggernauts Amgen, Johnson & Johnson and Sanofi, all of which arguably have good reasons to make an M&A move.